Another study involving 150 HCC patients [29] showed that CD3+ T lymphocytes, CD4+ T lymphocytes, and the ratio of CD4+/CD8+ T lymphocytes in the combined treatment group were significantly increased after treatment (P < 0.05), while the above indicators in the single treatment group were not significantly changed. This evidence concerns the gene CD8A and hepatocellular carcinoma.